<SEC-DOCUMENT>0001193125-23-260390.txt : 20231023
<SEC-HEADER>0001193125-23-260390.hdr.sgml : 20231023
<ACCEPTANCE-DATETIME>20231023083056
ACCESSION NUMBER:		0001193125-23-260390
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20231023
FILED AS OF DATE:		20231023
DATE AS OF CHANGE:		20231023

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		231338576

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d572469d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9745;&#8195;&#8195;&#8195;&#8195; Form
<FONT STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;23, 2023, Kazia Therapeutics Limited (the &#147;Company&#148;) issued an ASX release titled, &#147;Kazia Therapeutics
Announces Clinical Data at ESMO 2023 From Ongoing Phase 1 EVT801 Study,&#148; announcing that selected clinical data from the Company&#146;s ongoing Phase 1 clinical trial evaluating EVT801 in patients with advanced solid tumours was presented at
the European Society of Medical Oncology Congress 2023 (ESMO 2023) on Saturday, 21&nbsp;October 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Professor Carlos A Gomez-Roca,
(IUCT-Oncopole, Toulouse France) presented data from a correlation analysis of tumour biopsies from six&nbsp;(6)&nbsp;enrolled patients with high grade serous ovarian cancer <FONT STYLE="white-space:nowrap">(HGS-OC).</FONT> To date, twenty
(20)&nbsp;patients with advanced solid tumors have been dosed in in the ongoing Phase 1 clinical trial, and the trial has advanced to dose escalation cohort 6. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Key Points from the presentation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The hypothesis for EVT801&#146;s mechanism of action involves three (3)&nbsp;sequential anti-cancer mechanisms,
all of which are thought to contribute to the potential inhibition of tumour growth and metastasis: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preventing tumour growth by impairing both tumour angiogenesis and (lymph)angiogenesis, thereby stabilizing the
tumour vasculature, reducing metastasis, and reducing hypoxia in the tumour microenvironment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enhancing anti-cancer immunity as reflected by a decrease in immunosuppressive cytokines and cells in the
circulation and tumour environment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Promoting <FONT STYLE="white-space:nowrap">T-cell</FONT> infiltration into the tumour, ultimately supporting an
enhanced and long-lasting anti-tumour immune response. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a data analysis of biopsies from six <FONT STYLE="white-space:nowrap">(6)&nbsp;HGS-OC</FONT> patients, high
levels of VEGFR3 expression tended to be correlated with the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Higher levels of hypoxia; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increased immune checkpoint (PD1) resistance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Negatively correlated with CD8 positive <FONT STYLE="white-space:nowrap">T-cells</FONT> infiltration.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">While these findings would need to be confirmed in patients in other indications, these correlations are
encouraging and suggest that patients with hypoxic <FONT STYLE="white-space:nowrap">HGS-OC</FONT> tumours that are poorly infiltrated with CD8 positive <FONT STYLE="white-space:nowrap">T-cells</FONT> and with high VEGFR3 expression may benefit from
EVT801 treatment. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of this release is attached hereto as Exhibit&nbsp;99.1 and is incorporated by reference
herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, excluding Exhibit 99.1, into the Company&#146;s
registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d572469dex991.htm">ASX Release of Kazia Therapeutics Limited dated October&nbsp;23, 2023 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 23 October 2023</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d572469dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g572469g1022083623949.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">23 Oct 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 23 Oct 2023</B> &#150; Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, announces that selected
clinical data from the company&#146;s ongoing Phase 1 clinical trial evaluating EVT801 in patients with advanced solid tumours was presented at the European Society of Medical Oncology Congress 2023 (ESMO 2023) on Saturday, 21&nbsp;October 2023.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professor Carlos A Gomez-Roca, (IUCT-Oncopole, Toulouse France) presented data from a correlation analysis of tumour biopsies from six (6)&nbsp;enrolled
patients with high grade serous ovarian cancer <FONT STYLE="white-space:nowrap">(HGS-OC).</FONT> To date, twenty (20)&nbsp;patients with advanced solid tumors have been dosed in in the ongoing Phase 1 clinical trial, and the trial has advanced to
dose escalation cohort 6. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Key Points from the presentation: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The hypothesis for EVT801&#146;s mechanism of action involves three (3)&nbsp;sequential anti-cancer mechanisms,
all of which are thought to contribute to the potential inhibition of tumour growth and metastasis: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preventing tumour growth by impairing both tumour angiogenesis and (lymph)angiogenesis, thereby stabilizing the
tumour vasculature, reducing metastasis, and reducing hypoxia in the tumour microenvironment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enhancing anti-cancer immunity as reflected by a decrease in immunosuppressive cytokines and cells in the
circulation and tumour environment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Promoting <FONT STYLE="white-space:nowrap">T-cell</FONT> infiltration into the tumour, ultimately supporting an
enhanced and long-lasting anti-tumour immune response. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In a data analysis of biopsies from six <FONT STYLE="white-space:nowrap">(6)&nbsp;HGS-OC</FONT> patients, high
levels of VEGFR3 expression tended to be correlated with the following: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Higher levels of hypoxia; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Increased immune checkpoint (PD1) resistance; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></SUP>&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Negatively correlated with CD8 positive <FONT STYLE="white-space:nowrap">T-cells</FONT> infiltration.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">While these findings would need to be confirmed in patients in other indications, these correlations are
encouraging and suggest that patients with hypoxic <FONT STYLE="white-space:nowrap">HGS-OC</FONT> tumours that are poorly infiltrated&nbsp;with CD8 positive <FONT STYLE="white-space:nowrap">T-cells</FONT> and with high VEGFR3 expression may benefit
from EVT801 treatment. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;In spite of recent advances in treatments for ovarian cancer, there is an extremely high rate of
recurrence. The success of immune checkpoint inhibitors in other solid tumours has not carried through to high grade serous ovarian cancer. In data previously presented at AACR 2023, we demonstrated a high prevalence of <FONT
STYLE="white-space:nowrap">VEGFR-3</FONT> expression in <FONT STYLE="white-space:nowrap">HGS-OC</FONT> tumours, and we have now presented data showing a positive correlation between <FONT STYLE="white-space:nowrap">VEGFR-3</FONT> expression and
hypoxia and PD1 resistance signature and a negative correlation with CD8 positive <FONT STYLE="white-space:nowrap">T-cell</FONT> infiltration,&#148; said Dr.&nbsp;John Friend, Chief Executive Officer of Kazia. &#147;We look forward to completing
dose escalation in stage 1 of the ongoing study and progressing to stage 2 of the Phase 1 Study .&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2 study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study, GBM AGILE, is
ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US Food and Drug Administration (US FDA) in February 2018, and Fast Track Designation
for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and
July 2022, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021.
Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase 1 study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter @KaziaTx. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, and
Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are subject
to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product
development, related to regulatory approvals, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form
<FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of
new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g572469g1022083623949.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g572469g1022083623949.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X Q<# 2(  A$! Q$!_\0
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M)#M /48]#Z4)<W$801W$R"-MR!9"-I]1Z&GRZ6%S:W.TM)==TKX?RONU&?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRJG<D8'X5Y]5O4]2NM7U&:_O9#)/,VYCZ>P]A52M8II:F3:;T"NZTSX?/?\
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M<&YV7EW:DRK*C1)\TH$>S:>>.?6JFH:I:W6@0VPGFDNE"+C84 "YX;G:V.Q
M!]:+L+(H7&FM:W%I%),"+B)90R(6*AL\8ZD\=JA%C=OS':W#H20K+"V#^E;C
M7^EFZTF_%])YMK''');_ &9L_*3DALX/6IU\26Z6PB6>Y7$6W"@@9\[?Z^E%
MV%D8-MI5U>QYM(9II &9T6(_*J]3GH?I54PS"(2F&01$[0Y0[<^F>F:Z==?L
M2\BF69%DDN3N$9^42#Y3C/YT)XBLX])M8>LD21QO$(2=VU]V[<6P/P&:+L+(
MP;G39[2PM[J8,GGNRB-T*L,=^>QJG6YKFI6MY:00P74]PR3RRLTJ%=H<Y &2
M>E8=-"84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 5
M5+,%'4G KI+[1=2TO1&8:@S0\&6!20!G^=<T"0<@X(KI95\0ZKH8=S&UL!G
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M@9H?V#?"[T^V*Q"2_56AR_'/]X]CT_,4]/#M]-<)#;O;3^9"\\<D4N4=4X8
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M<&KZ7VF3>)9=0FE=(U4/&S0E@\H4#)4'(7/./PI]MKBPZ?+%+?2SN&<QI]G
MPY8$2ACSGC.#1=A9&5-I=S;W,<$S01F3.V0S+Y?!P<MT&#Q4\GA^]A\\RR6<
M:P!"SM<J%.X97![DBK6L:G8ZA<:?&K?N(69I9$M_+SN8$_+D\\<^YJ:UU^(:
ME?3RW#QVTTP?[/Y <2HO 4D_=XQ1=A9&(]A<QZ=%?N@%O+(8T;<,DCD\=<>]
M5JV]0U>RO-!M[.*TDAGAD!'[W<FT \@8ZY-8E-"84444""BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
